ABIO Share Price | ARCA biopharma, Inc. Stock Analysis & Recommendation

Q: What does ARCA biopharma, Inc. do?

Overview: ARCA biopharma, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.Financial Snapshot: Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) Market cap: USD 418.93 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 66.58% Debt Equity: -0.96 Return on Equity: -21.31% Price to Book: 1.15Contact Details: Address: 10170 Church Ranch Way, Suite 100, WESTMINSTER CO: 80021 Tel: 1 720 9402100 Fax: 1 302 6555049 Website: http://arcabio.com/

Q: Is ARCA biopharma, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for ARCA biopharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by a bullish MACD on the weekly timeframe and a bullish RSI on the monthly timeframe. However, the monthly KST is bearish, and the OBV shows a mildly bearish signal, indicating some mixed signals. The moving averages are bullish on the daily timeframe, which adds to the positive outlook. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.66% and 8.72% respectively, but has significantly underperformed over longer periods, including a -14.49% year-to-date return compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

139.02 k

Shareholding (Mar 2025)

FII

5.93%

Held by 25 FIIs

DII

55.55%

Held by 27 DIIs

Promoter

14.75%

How big is ARCA biopharma, Inc.?

22-Jun-2025

As of Jun 18, ARCA biopharma, Inc. has a market capitalization of 418.93 million and reported net sales of 0.00 million with a net profit of -78.08 million over the last four quarters. Shareholder's funds were 382.22 million, and total assets amounted to 396.02 million as of Dec 24.

View full answer

What does ARCA biopharma, Inc. do?

22-Jun-2025

ARCA biopharma, Inc. is a biopharmaceutical company focused on developing genetically-targeted therapies for cardiovascular diseases, with a market cap of approximately $418.93 million and a recent net profit of -$21 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap.

View full answer

Who are in the management team of ARCA biopharma, Inc.?

22-Jun-2025

As of March 2022, the management team of ARCA biopharma, Inc. includes Robert Conway (Chairman), Dr. Michael Bristow (CEO), Dr. Linda Grais (Lead Independent Director), Dr. Anders Hove, Mr. Daniel Mitchell, and Dr. Raymond Woosley (Directors). They are responsible for the company's strategic direction and operations.

View full answer

Is ARCA biopharma, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, ARCA biopharma, Inc. shows a mildly bullish trend with mixed signals from indicators, having outperformed the S&P 500 recently but underperformed year-to-date.

View full answer

Compare ARCA biopharma, Inc. with Similar Stocks

BeyondSpring, Inc.TherapeuticsMD, Inc.Apollomics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 572 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.95

Return on Equity

-29.09%

Price to Book

1.67

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-25 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

201.65%

6 Months

38.36%

1 Year

-14.06%

2 Years

33.5%

3 Years

17.02%

4 Years

-25.47%

5 Years

-65.97%

ARCA biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-281.82%

EBIT to Interest (avg)

-26.61

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.96

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.21

EV to EBIT

-1.04

EV to EBITDA

-1.04

EV to Capital Employed

5.75

EV to Sales

PEG Ratio

Dividend Yield

63.35%

ROCE (Latest)

-550.49%

ROE (Latest)

-21.31%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 12 Schemes (23.77%)

Foreign Institutions

Held by 25 Foreign Institutions (5.93%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -811.11% vs -80.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.40",
          "val2": "-2.70",
          "chgp": "-951.85%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.40",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.60",
          "val2": "-2.70",
          "chgp": "-811.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -1,479.25% vs 46.46% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-88.10",
          "val2": "-7.20",
          "chgp": "-1,123.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-83.70",
          "val2": "-5.30",
          "chgp": "-1,479.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-28.40

-2.70

-951.85%

Interest

0.00

Exceptional Items

0.00

-0.40

100.00%

Consolidate Net Profit

-24.60

-2.70

-811.11%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -811.11% vs -80.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-88.10

-7.20

-1,123.61%

Interest

1.50

0.00

Exceptional Items

0.00

Consolidate Net Profit

-83.70

-5.30

-1,479.25%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -1,479.25% vs 46.46% in Dec 2023

All Annual Results

Company CV

About ARCA biopharma, Inc.

ARCA biopharma, Inc.

Pharmaceuticals & Biotechnology

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Company Coordinates

Company Details

10170 Church Ranch Way, Suite 100 , WESTMINSTER CO : 80021

Tel: 1 720 9402100

http://arcabio.com/

Registrar Details

ARCA biopharma, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is ARCA biopharma, Inc.?

Watch in Real-Time

What does ARCA biopharma, Inc. do?

Who are in the management team of ARCA biopharma, Inc.?

Is ARCA biopharma, Inc. technically bullish or bearish?

Compare ARCA biopharma, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About ARCA biopharma, Inc.

Company Coordinates